Pharming Group (PHAR)
7.53
-0.23
(-2.96%)
USD |
NASDAQ |
Nov 22, 16:00
7.48
-0.05
(-0.66%)
After-Hours: 20:00
Pharming Group Enterprise Value: 434.45M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 434.45M |
| November 21, 2024 | 450.05M |
| November 20, 2024 | 444.63M |
| November 19, 2024 | 435.53M |
| November 18, 2024 | 449.38M |
| November 15, 2024 | 478.55M |
| November 14, 2024 | 459.55M |
| November 13, 2024 | 473.12M |
| November 12, 2024 | 466.34M |
| November 11, 2024 | 466.13M |
| November 08, 2024 | 477.87M |
| November 07, 2024 | 487.36M |
| November 06, 2024 | 459.56M |
| November 05, 2024 | 475.15M |
| November 04, 2024 | 488.90M |
| November 01, 2024 | 501.61M |
| October 31, 2024 | 528.07M |
| October 30, 2024 | 524.67M |
| October 29, 2024 | 512.46M |
| October 28, 2024 | 523.32M |
| October 25, 2024 | 513.82M |
| October 24, 2024 | 486.69M |
| October 23, 2024 | 531.46M |
| October 22, 2024 | 529.88M |
| October 21, 2024 | 528.07M |
| Date | Value |
|---|---|
| October 18, 2024 | 545.11M |
| October 17, 2024 | 507.71M |
| October 16, 2024 | 512.46M |
| October 15, 2024 | 513.82M |
| October 14, 2024 | 500.94M |
| October 11, 2024 | 500.25M |
| October 10, 2024 | 519.25M |
| October 09, 2024 | 510.43M |
| October 08, 2024 | 514.50M |
| October 07, 2024 | 493.47M |
| October 04, 2024 | 469.05M |
| October 03, 2024 | 497.17M |
| October 02, 2024 | 473.12M |
| October 01, 2024 | 506.36M |
| September 30, 2024 | 483.29M |
| September 27, 2024 | 506.08M |
| September 26, 2024 | 474.87M |
| September 25, 2024 | 452.48M |
| September 24, 2024 | 445.70M |
| September 23, 2024 | 449.64M |
| September 20, 2024 | 444.68M |
| September 19, 2024 | 475.54M |
| September 18, 2024 | 468.76M |
| September 17, 2024 | 467.06M |
| September 16, 2024 | 459.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
376.23M
Minimum
Jun 16 2022
1.027B
Maximum
Dec 23 2020
639.96M
Average
665.04M
Median
Apr 26 2023
Enterprise Value Benchmarks
| uniQure NV | -102.39M |
| ProQR Therapeutics NV | 288.57M |
| Merus NV | 2.482B |
| argenx SE | 33.13B |
| Pharvaris NV | 867.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.034M |
| Revenue (Quarterly) | 74.85M |
| Total Expenses (Quarterly) | 70.74M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 90.89% |
| Profit Margin (Quarterly) | -1.38% |
| Earnings Yield | -3.59% |
| Normalized Earnings Yield | -3.590 |